Comparison

Semaglutide vs tirzepatide vs retatrutide: a research comparison

Semaglutide, tirzepatide and retatrutide are the three most referenced incretin-receptor agonists in metabolic research. They form a clear ladder of receptor coverage, which is why they are so often studied against one another.

The receptor ladder

Semaglutide is a single-receptor agonist (GLP-1). Tirzepatide is a dual agonist (GLP-1 and GIP). Retatrutide is a triple agonist (GLP-1, GIP and glucagon). Each newer compound adds a receptor to the profile.

Why they are compared

Because each compound extends the receptor coverage of the one before it, they serve as reference points against each other in comparative incretin research — a single-, dual- and triple-agonist series.

Shared characteristics

All three are synthetic, long-acting analogues supplied as lyophilised powder for laboratory research. They differ mainly in receptor breadth and structure, not in their general handling.

Semaglutide Tirzepatide Retatrutide

This overview is provided for educational and laboratory-research purposes only. It summarises published research and proposed mechanisms; it is not medical advice and does not describe or recommend human or veterinary use. Products are supplied strictly for laboratory research use only — not for human or veterinary consumption, and not a drug, food or cosmetic.